Ionic low-osmolar versus nonionic iso-osmolar contrast media to obviate worsening nephropathy after angioplasty in chronic renal failure patients: the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) study

This randomized, prospective, double-blind, multicenter study compared nephrotoxicity of the nonionic iso-osmolar contrast media (CM) iodixanol versus the ionic low-osmolar CM ioxaglate in patients with chronic renal insufficiency undergoing coronary angiography. The properties of iodinated CM might...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JACC. Cardiovascular interventions 2009-05, Vol.2 (5), p.415
Hauptverfasser: Mehran, Roxana, Nikolsky, Eugenia, Kirtane, Ajay J, Caixeta, Adriano, Wong, S Chiu, Teirstein, Paul S, Downey, William E, Batchelor, Wayne B, Casterella, Peter J, Kim, Young-Hak, Fahy, Martin, Dangas, George D
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 5
container_start_page 415
container_title JACC. Cardiovascular interventions
container_volume 2
creator Mehran, Roxana
Nikolsky, Eugenia
Kirtane, Ajay J
Caixeta, Adriano
Wong, S Chiu
Teirstein, Paul S
Downey, William E
Batchelor, Wayne B
Casterella, Peter J
Kim, Young-Hak
Fahy, Martin
Dangas, George D
description This randomized, prospective, double-blind, multicenter study compared nephrotoxicity of the nonionic iso-osmolar contrast media (CM) iodixanol versus the ionic low-osmolar CM ioxaglate in patients with chronic renal insufficiency undergoing coronary angiography. The properties of iodinated CM might contribute to the incidence of contrast-induced nephropathy (CIN). Patients with renal impairment undergoing coronary angiography were randomly assigned to iodixanol (n = 72) or ioxaglate (n = 74). Baseline characteristics were well-matched between the 2 groups. The predicted risk score for CIN was similar in the iodixanol and in the ioxaglate groups (11.9 +/- 4.1 vs. 11.8 +/- 4.1), as was the use of N-acetylcysteine (70% vs. 73%). The primary end point of the study, median peak increase of serum creatinine from day 0 through day 3 after angiography, did not differ between the iodixanol (0.09 mg/dl; interquartile range 0.00 to 0.30 mg/dl) and the ioxaglate (0.15 mg/dl; interquartile range 0.00 to 0.40 mg/dl; p = 0.07) groups. The percentages of patients with a peak increase of serum creatinine >or=0.5 mg/dl (15.9% in iodixanol vs. 18.2% in ioxaglate), >or=1.0 mg/dl (1.4% vs. 4.5%), and >or=25% or >or=0.5 mg/dl (15.9% vs. 24.2%, respectively) also did not differ significantly between the 2 groups. In high-risk patients undergoing coronary angiographic procedures, use of the nonionic iso-osmolar CM iodixanol does not reduce renal deterioration in patients with renal impairment, compared with the ionic low-osmolar CM ioxaglate. Given that the study was underpowered to compare nephrotoxicity of the 2 groups under the active medical protection of CIN, a larger randomized study is warranted that will enroll patients with higher risks of CIN under a strict control of hydration regimens and adjunctive medications.
doi_str_mv 10.1016/j.jcin.2009.03.007
format Article
fullrecord <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_19463464</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19463464</sourcerecordid><originalsourceid>FETCH-LOGICAL-h249t-650bdf6a33276abd961379d89a9cc85a688ee47b56d4f10e9d9c6453562a09ba3</originalsourceid><addsrcrecordid>eNqlkT1PwzAQhg0SolDYEQO6EYYE58uJ2VDER6WqXWCuLonTuErtyHZb5d8TKIWBkemGR_e-j-4IuQ6oH9CA3a_8VSmVH1LKfRr5lKbH5CzIUualjCYjcm7tilJGeRqeklHAYxbFLD47uppoJUto9c7Tdq1bNLAVxm4sqAF8MWn1Dyu1cgatg7WoJILToIutRCdgp40VSqolKNE1Rnfomh6wdsIAqqXUXTvs9SAVlAP-DDZCYQs1ynZjBAwLUihnH8A1Aib5fAa3e7lfIW9vlB8shv75n_7Z__rvwLpN1V-QkxpbKy6_55i8Pz-95a_edP4yyR-nXhPG3HksoUVVM4yiMGVYVJwFUcqrjCMvyyxBlmVCxGmRsCquAyp4xUsWJ1HCQqS8wGhMbva53aYYjrrojFyj6ReHF0UfyNObqw</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Ionic low-osmolar versus nonionic iso-osmolar contrast media to obviate worsening nephropathy after angioplasty in chronic renal failure patients: the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) study</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Mehran, Roxana ; Nikolsky, Eugenia ; Kirtane, Ajay J ; Caixeta, Adriano ; Wong, S Chiu ; Teirstein, Paul S ; Downey, William E ; Batchelor, Wayne B ; Casterella, Peter J ; Kim, Young-Hak ; Fahy, Martin ; Dangas, George D</creator><creatorcontrib>Mehran, Roxana ; Nikolsky, Eugenia ; Kirtane, Ajay J ; Caixeta, Adriano ; Wong, S Chiu ; Teirstein, Paul S ; Downey, William E ; Batchelor, Wayne B ; Casterella, Peter J ; Kim, Young-Hak ; Fahy, Martin ; Dangas, George D</creatorcontrib><description>This randomized, prospective, double-blind, multicenter study compared nephrotoxicity of the nonionic iso-osmolar contrast media (CM) iodixanol versus the ionic low-osmolar CM ioxaglate in patients with chronic renal insufficiency undergoing coronary angiography. The properties of iodinated CM might contribute to the incidence of contrast-induced nephropathy (CIN). Patients with renal impairment undergoing coronary angiography were randomly assigned to iodixanol (n = 72) or ioxaglate (n = 74). Baseline characteristics were well-matched between the 2 groups. The predicted risk score for CIN was similar in the iodixanol and in the ioxaglate groups (11.9 +/- 4.1 vs. 11.8 +/- 4.1), as was the use of N-acetylcysteine (70% vs. 73%). The primary end point of the study, median peak increase of serum creatinine from day 0 through day 3 after angiography, did not differ between the iodixanol (0.09 mg/dl; interquartile range 0.00 to 0.30 mg/dl) and the ioxaglate (0.15 mg/dl; interquartile range 0.00 to 0.40 mg/dl; p = 0.07) groups. The percentages of patients with a peak increase of serum creatinine &gt;or=0.5 mg/dl (15.9% in iodixanol vs. 18.2% in ioxaglate), &gt;or=1.0 mg/dl (1.4% vs. 4.5%), and &gt;or=25% or &gt;or=0.5 mg/dl (15.9% vs. 24.2%, respectively) also did not differ significantly between the 2 groups. In high-risk patients undergoing coronary angiographic procedures, use of the nonionic iso-osmolar CM iodixanol does not reduce renal deterioration in patients with renal impairment, compared with the ionic low-osmolar CM ioxaglate. Given that the study was underpowered to compare nephrotoxicity of the 2 groups under the active medical protection of CIN, a larger randomized study is warranted that will enroll patients with higher risks of CIN under a strict control of hydration regimens and adjunctive medications.</description><identifier>EISSN: 1876-7605</identifier><identifier>DOI: 10.1016/j.jcin.2009.03.007</identifier><identifier>PMID: 19463464</identifier><language>eng</language><publisher>United States</publisher><subject>Aged ; Angioplasty, Balloon ; Contrast Media - adverse effects ; Coronary Angiography ; Coronary Artery Disease - complications ; Coronary Artery Disease - diagnosis ; Creatinine ; Double-Blind Method ; Female ; Humans ; Ioxaglic Acid - adverse effects ; Kidney Diseases - chemically induced ; Kidney Failure, Chronic - physiopathology ; Kidney Failure, Chronic - prevention &amp; control ; Male ; Risk Assessment ; Time Factors ; Triiodobenzoic Acids - adverse effects</subject><ispartof>JACC. Cardiovascular interventions, 2009-05, Vol.2 (5), p.415</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,27931,27932</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19463464$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mehran, Roxana</creatorcontrib><creatorcontrib>Nikolsky, Eugenia</creatorcontrib><creatorcontrib>Kirtane, Ajay J</creatorcontrib><creatorcontrib>Caixeta, Adriano</creatorcontrib><creatorcontrib>Wong, S Chiu</creatorcontrib><creatorcontrib>Teirstein, Paul S</creatorcontrib><creatorcontrib>Downey, William E</creatorcontrib><creatorcontrib>Batchelor, Wayne B</creatorcontrib><creatorcontrib>Casterella, Peter J</creatorcontrib><creatorcontrib>Kim, Young-Hak</creatorcontrib><creatorcontrib>Fahy, Martin</creatorcontrib><creatorcontrib>Dangas, George D</creatorcontrib><title>Ionic low-osmolar versus nonionic iso-osmolar contrast media to obviate worsening nephropathy after angioplasty in chronic renal failure patients: the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) study</title><title>JACC. Cardiovascular interventions</title><addtitle>JACC Cardiovasc Interv</addtitle><description>This randomized, prospective, double-blind, multicenter study compared nephrotoxicity of the nonionic iso-osmolar contrast media (CM) iodixanol versus the ionic low-osmolar CM ioxaglate in patients with chronic renal insufficiency undergoing coronary angiography. The properties of iodinated CM might contribute to the incidence of contrast-induced nephropathy (CIN). Patients with renal impairment undergoing coronary angiography were randomly assigned to iodixanol (n = 72) or ioxaglate (n = 74). Baseline characteristics were well-matched between the 2 groups. The predicted risk score for CIN was similar in the iodixanol and in the ioxaglate groups (11.9 +/- 4.1 vs. 11.8 +/- 4.1), as was the use of N-acetylcysteine (70% vs. 73%). The primary end point of the study, median peak increase of serum creatinine from day 0 through day 3 after angiography, did not differ between the iodixanol (0.09 mg/dl; interquartile range 0.00 to 0.30 mg/dl) and the ioxaglate (0.15 mg/dl; interquartile range 0.00 to 0.40 mg/dl; p = 0.07) groups. The percentages of patients with a peak increase of serum creatinine &gt;or=0.5 mg/dl (15.9% in iodixanol vs. 18.2% in ioxaglate), &gt;or=1.0 mg/dl (1.4% vs. 4.5%), and &gt;or=25% or &gt;or=0.5 mg/dl (15.9% vs. 24.2%, respectively) also did not differ significantly between the 2 groups. In high-risk patients undergoing coronary angiographic procedures, use of the nonionic iso-osmolar CM iodixanol does not reduce renal deterioration in patients with renal impairment, compared with the ionic low-osmolar CM ioxaglate. Given that the study was underpowered to compare nephrotoxicity of the 2 groups under the active medical protection of CIN, a larger randomized study is warranted that will enroll patients with higher risks of CIN under a strict control of hydration regimens and adjunctive medications.</description><subject>Aged</subject><subject>Angioplasty, Balloon</subject><subject>Contrast Media - adverse effects</subject><subject>Coronary Angiography</subject><subject>Coronary Artery Disease - complications</subject><subject>Coronary Artery Disease - diagnosis</subject><subject>Creatinine</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Humans</subject><subject>Ioxaglic Acid - adverse effects</subject><subject>Kidney Diseases - chemically induced</subject><subject>Kidney Failure, Chronic - physiopathology</subject><subject>Kidney Failure, Chronic - prevention &amp; control</subject><subject>Male</subject><subject>Risk Assessment</subject><subject>Time Factors</subject><subject>Triiodobenzoic Acids - adverse effects</subject><issn>1876-7605</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqlkT1PwzAQhg0SolDYEQO6EYYE58uJ2VDER6WqXWCuLonTuErtyHZb5d8TKIWBkemGR_e-j-4IuQ6oH9CA3a_8VSmVH1LKfRr5lKbH5CzIUualjCYjcm7tilJGeRqeklHAYxbFLD47uppoJUto9c7Tdq1bNLAVxm4sqAF8MWn1Dyu1cgatg7WoJILToIutRCdgp40VSqolKNE1Rnfomh6wdsIAqqXUXTvs9SAVlAP-DDZCYQs1ynZjBAwLUihnH8A1Aib5fAa3e7lfIW9vlB8shv75n_7Z__rvwLpN1V-QkxpbKy6_55i8Pz-95a_edP4yyR-nXhPG3HksoUVVM4yiMGVYVJwFUcqrjCMvyyxBlmVCxGmRsCquAyp4xUsWJ1HCQqS8wGhMbva53aYYjrrojFyj6ReHF0UfyNObqw</recordid><startdate>200905</startdate><enddate>200905</enddate><creator>Mehran, Roxana</creator><creator>Nikolsky, Eugenia</creator><creator>Kirtane, Ajay J</creator><creator>Caixeta, Adriano</creator><creator>Wong, S Chiu</creator><creator>Teirstein, Paul S</creator><creator>Downey, William E</creator><creator>Batchelor, Wayne B</creator><creator>Casterella, Peter J</creator><creator>Kim, Young-Hak</creator><creator>Fahy, Martin</creator><creator>Dangas, George D</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>200905</creationdate><title>Ionic low-osmolar versus nonionic iso-osmolar contrast media to obviate worsening nephropathy after angioplasty in chronic renal failure patients: the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) study</title><author>Mehran, Roxana ; Nikolsky, Eugenia ; Kirtane, Ajay J ; Caixeta, Adriano ; Wong, S Chiu ; Teirstein, Paul S ; Downey, William E ; Batchelor, Wayne B ; Casterella, Peter J ; Kim, Young-Hak ; Fahy, Martin ; Dangas, George D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h249t-650bdf6a33276abd961379d89a9cc85a688ee47b56d4f10e9d9c6453562a09ba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Aged</topic><topic>Angioplasty, Balloon</topic><topic>Contrast Media - adverse effects</topic><topic>Coronary Angiography</topic><topic>Coronary Artery Disease - complications</topic><topic>Coronary Artery Disease - diagnosis</topic><topic>Creatinine</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Humans</topic><topic>Ioxaglic Acid - adverse effects</topic><topic>Kidney Diseases - chemically induced</topic><topic>Kidney Failure, Chronic - physiopathology</topic><topic>Kidney Failure, Chronic - prevention &amp; control</topic><topic>Male</topic><topic>Risk Assessment</topic><topic>Time Factors</topic><topic>Triiodobenzoic Acids - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mehran, Roxana</creatorcontrib><creatorcontrib>Nikolsky, Eugenia</creatorcontrib><creatorcontrib>Kirtane, Ajay J</creatorcontrib><creatorcontrib>Caixeta, Adriano</creatorcontrib><creatorcontrib>Wong, S Chiu</creatorcontrib><creatorcontrib>Teirstein, Paul S</creatorcontrib><creatorcontrib>Downey, William E</creatorcontrib><creatorcontrib>Batchelor, Wayne B</creatorcontrib><creatorcontrib>Casterella, Peter J</creatorcontrib><creatorcontrib>Kim, Young-Hak</creatorcontrib><creatorcontrib>Fahy, Martin</creatorcontrib><creatorcontrib>Dangas, George D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>JACC. Cardiovascular interventions</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mehran, Roxana</au><au>Nikolsky, Eugenia</au><au>Kirtane, Ajay J</au><au>Caixeta, Adriano</au><au>Wong, S Chiu</au><au>Teirstein, Paul S</au><au>Downey, William E</au><au>Batchelor, Wayne B</au><au>Casterella, Peter J</au><au>Kim, Young-Hak</au><au>Fahy, Martin</au><au>Dangas, George D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ionic low-osmolar versus nonionic iso-osmolar contrast media to obviate worsening nephropathy after angioplasty in chronic renal failure patients: the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) study</atitle><jtitle>JACC. Cardiovascular interventions</jtitle><addtitle>JACC Cardiovasc Interv</addtitle><date>2009-05</date><risdate>2009</risdate><volume>2</volume><issue>5</issue><spage>415</spage><pages>415-</pages><eissn>1876-7605</eissn><abstract>This randomized, prospective, double-blind, multicenter study compared nephrotoxicity of the nonionic iso-osmolar contrast media (CM) iodixanol versus the ionic low-osmolar CM ioxaglate in patients with chronic renal insufficiency undergoing coronary angiography. The properties of iodinated CM might contribute to the incidence of contrast-induced nephropathy (CIN). Patients with renal impairment undergoing coronary angiography were randomly assigned to iodixanol (n = 72) or ioxaglate (n = 74). Baseline characteristics were well-matched between the 2 groups. The predicted risk score for CIN was similar in the iodixanol and in the ioxaglate groups (11.9 +/- 4.1 vs. 11.8 +/- 4.1), as was the use of N-acetylcysteine (70% vs. 73%). The primary end point of the study, median peak increase of serum creatinine from day 0 through day 3 after angiography, did not differ between the iodixanol (0.09 mg/dl; interquartile range 0.00 to 0.30 mg/dl) and the ioxaglate (0.15 mg/dl; interquartile range 0.00 to 0.40 mg/dl; p = 0.07) groups. The percentages of patients with a peak increase of serum creatinine &gt;or=0.5 mg/dl (15.9% in iodixanol vs. 18.2% in ioxaglate), &gt;or=1.0 mg/dl (1.4% vs. 4.5%), and &gt;or=25% or &gt;or=0.5 mg/dl (15.9% vs. 24.2%, respectively) also did not differ significantly between the 2 groups. In high-risk patients undergoing coronary angiographic procedures, use of the nonionic iso-osmolar CM iodixanol does not reduce renal deterioration in patients with renal impairment, compared with the ionic low-osmolar CM ioxaglate. Given that the study was underpowered to compare nephrotoxicity of the 2 groups under the active medical protection of CIN, a larger randomized study is warranted that will enroll patients with higher risks of CIN under a strict control of hydration regimens and adjunctive medications.</abstract><cop>United States</cop><pmid>19463464</pmid><doi>10.1016/j.jcin.2009.03.007</doi></addata></record>
fulltext fulltext
identifier EISSN: 1876-7605
ispartof JACC. Cardiovascular interventions, 2009-05, Vol.2 (5), p.415
issn 1876-7605
language eng
recordid cdi_pubmed_primary_19463464
source MEDLINE; Access via ScienceDirect (Elsevier); EZB-FREE-00999 freely available EZB journals
subjects Aged
Angioplasty, Balloon
Contrast Media - adverse effects
Coronary Angiography
Coronary Artery Disease - complications
Coronary Artery Disease - diagnosis
Creatinine
Double-Blind Method
Female
Humans
Ioxaglic Acid - adverse effects
Kidney Diseases - chemically induced
Kidney Failure, Chronic - physiopathology
Kidney Failure, Chronic - prevention & control
Male
Risk Assessment
Time Factors
Triiodobenzoic Acids - adverse effects
title Ionic low-osmolar versus nonionic iso-osmolar contrast media to obviate worsening nephropathy after angioplasty in chronic renal failure patients: the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T11%3A39%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ionic%20low-osmolar%20versus%20nonionic%20iso-osmolar%20contrast%20media%20to%20obviate%20worsening%20nephropathy%20after%20angioplasty%20in%20chronic%20renal%20failure%20patients:%20the%20ICON%20(Ionic%20versus%20non-ionic%20Contrast%20to%20Obviate%20worsening%20Nephropathy%20after%20angioplasty%20in%20chronic%20renal%20failure%20patients)%20study&rft.jtitle=JACC.%20Cardiovascular%20interventions&rft.au=Mehran,%20Roxana&rft.date=2009-05&rft.volume=2&rft.issue=5&rft.spage=415&rft.pages=415-&rft.eissn=1876-7605&rft_id=info:doi/10.1016/j.jcin.2009.03.007&rft_dat=%3Cpubmed%3E19463464%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/19463464&rfr_iscdi=true